Nearly 50% of NSCLC patients with acquired resistance to EGFR-TKIs have a secondary mutation in T790M (a secondary point mutation in EGFR exon 20 replaces methionine at amino acid position 790) [66,67]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.